Literature DB >> 30273976

Physician characteristics, industry transfers, and pharmaceutical prescribing: Empirical evidence from medicare and the physician payment sunshine act.

Christopher Scott Brunt1.   

Abstract

OBJECTIVE: To evaluate physician characteristics associated with pharmaceutical industry transfers and prescribing behavior after public reporting under the Sunshine Act. DATA SOURCES: 2014-2016 secondary data on industry transfers to physicians from the Open Payments Dataset supplemented with Medicare Part D prescription data, Medicare service data, and practice attributes from the Physician Compare Database. STUDY
DESIGN: Using regression analysis with county/physician fixed effects, this study examines characteristics associated with the probability/magnitude of transfers and the association between transfers and prescriptions. DATA COLLECTION: Using an iterative matching approach, this study identifies physicians who delivered outpatient Medicare services in 2014 (n = 409 041) and tracks their annual transfers between 2014 and 2016 (N = 1 227 123) across six transfer categories. In addition, it examines their Medicare Part D prescription behavior between 2014 and 2015 (N = 741 659). PRINCIPAL
FINDINGS: Industry transfers dramatically declined in 2015 and 2016. Transfers are significantly associated with increased prescription costs, branded prescribing, and prescribing for High-Risk Medications (HRMs).
CONCLUSIONS: Industry transfers have declined after public reporting. Transfers are associated with higher prescription costs and incidence of HRMs. Future research is needed to determine the causal impact on quality and cost-effectiveness of prescribed medications. © Health Research and Educational Trust.

Entities:  

Keywords:  zzm321990Physician Payment Sunshine Actzzm321990; conflict of interest; physician-industry transfers

Mesh:

Year:  2018        PMID: 30273976      PMCID: PMC6505404          DOI: 10.1111/1475-6773.13064

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  27 in total

1.  Understanding why GPs see pharmaceutical representatives: a qualitative interview study.

Authors:  Helen Prosser; Tom Walley
Journal:  Br J Gen Pract       Date:  2003-04       Impact factor: 5.386

2.  The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review.

Authors:  Puneet Manchanda; Elisabeth Honka
Journal:  Yale J Health Policy Law Ethics       Date:  2005

Review 3.  Association between physicians' interaction with pharmaceutical companies and their clinical practices: A systematic review and meta-analysis.

Authors:  Hneine Brax; Racha Fadlallah; Lina Al-Khaled; Lara A Kahale; Hala Nas; Fadi El-Jardali; Elie A Akl
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

4.  The Sunshine Act--effects on physicians.

Authors:  Shantanu Agrawal; Niall Brennan; Peter Budetti
Journal:  N Engl J Med       Date:  2013-05-30       Impact factor: 91.245

Review 5.  Limiting the influence of pharmaceutical industry gifts on physicians: self-regulation or government intervention?

Authors:  David Grande
Journal:  J Gen Intern Med       Date:  2009-09-12       Impact factor: 5.128

6.  US drug marketing: how does promotion correspond with health value?

Authors:  Tyler Greenway; Joseph S Ross
Journal:  BMJ       Date:  2017-05-02

7.  Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.

Authors:  James S Yeh; Jessica M Franklin; Jerry Avorn; Joan Landon; Aaron S Kesselheim
Journal:  JAMA Intern Med       Date:  2016-06-01       Impact factor: 21.873

8.  A national survey of physician-industry relationships.

Authors:  Eric G Campbell; Russell L Gruen; James Mountford; Lawrence G Miller; Paul D Cleary; David Blumenthal
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

9.  Physicians-Pharmaceutical Sales Representatives Interactions and Conflict of Interest: Challenges and Solutions.

Authors:  Avinash R Patwardhan
Journal:  Inquiry       Date:  2016-09-16       Impact factor: 1.730

10.  Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study.

Authors:  William Fleischman; Shantanu Agrawal; Marissa King; Arjun K Venkatesh; Harlan M Krumholz; Douglas McKee; Douglas Brown; Joseph S Ross
Journal:  BMJ       Date:  2016-08-18
View more
  7 in total

1.  Physician characteristics, industry transfers, and pharmaceutical prescribing: Empirical evidence from medicare and the physician payment sunshine act.

Authors:  Christopher Scott Brunt
Journal:  Health Serv Res       Date:  2018-10-01       Impact factor: 3.402

2.  Increasing Financial Payments From Industry to Medical Oncologists in the United States, 2014-2017.

Authors:  Mohammed W Rahman; Niti U Trivedi; Peter B Bach; Aaron P Mitchell
Journal:  J Natl Compr Canc Netw       Date:  2021-12-29       Impact factor: 12.693

3.  Associations Between Industry Payments to Physicians for Antiplatelet Drugs and Utilization of Cardiac Procedures and Stents.

Authors:  Mao Yanagisawa; Daniel M Blumenthal; Hirotaka Kato; Kosuke Inoue; Yusuke Tsugawa
Journal:  J Gen Intern Med       Date:  2021-08-10       Impact factor: 6.473

4.  Voluntary disclosures of payments from pharmaceutical companies to healthcare professionals in Germany: a descriptive study of disclosures in 2015 and 2016.

Authors:  Marlene Stoll; Lara Hubenschmid; Cora Koch; Klaus Lieb
Journal:  BMJ Open       Date:  2020-09-17       Impact factor: 2.692

5.  Despise the free lunch.

Authors:  Majid A Almadi; Abdulaziz Altowaijri
Journal:  Saudi J Gastroenterol       Date:  2021 Nov-Dec       Impact factor: 2.485

6.  Association between physician characteristics and payments from industry in 2015-2017: observational study.

Authors:  Kosuke Inoue; Daniel M Blumenthal; David Elashoff; Yusuke Tsugawa
Journal:  BMJ Open       Date:  2019-09-20       Impact factor: 2.692

7.  Sunshine on KOLs: assessment of the nature, extent and evolution of financial ties between the leaders of professional medical associations and the pharmaceutical industry in France from 2014 to 2019: a retrospective study.

Authors:  Marie Clinckemaillie; Alexandre Scanff; Florian Naudet; Adriaan Barbaroux
Journal:  BMJ Open       Date:  2022-02-02       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.